|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Biosimilar and Biobetter/Biosuperior Antibodies
La Merie Publishing, Oct 2010, Pages: 106
The present Competitive Intelligence Report about Biosimilar and Biobetter/Biosuperior Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies directed against CD20, Her2, VEGF, TNF, EGF-R, RSV and GPIIb/IIIa as of October 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of therapeutic antibodies are beginning to expire over the next few years. With 2009 combined sales of US$ 35.5 bln for only six pharmacologic classes, therapeutic antibodies are quite an attractive field for companies to embark on with biosimilar or biobetter/biosuperior antibodies. Apart from the economic attractiveness, it is also the validated target of therapeutic antibodies which attracts technology companies to create and develop improved versions of established therapeutic antibodies against CD20, Her2, VEGF, TNF, EGF-R and TNF. Further players in this field are Big Pharma companies trying to defend their market with next generation molecules, as well as biopharmaceutical companies from “off-patent” countries with the intention to offer valuable therapeutics at locally affordable prices.
The report includes a compilation of currently active projects in research and development of biosimilar and biobetter/biosuperior antibodies against CD20, Her2, VEGF, TNF, RSV and GPIIb/IIIa. In addition, the report lists company-specific R&D pipelines of biosimilar and biobetter/biosuperior antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Success with Biobetters: Young Biobetters Companies and Pipelines
Biosimilar Opportunities: Pipelines and Companies
Biopharmaceuticals in the US and European Markets
Competitor Analysis: CD20 Antibodies
Biosimilars (2009 - 2014)
Taking Advantage of Protein-Based Therapy Opportunities
Biosimilars and Biobetters: Positioning for a New Market 2009
Antiviral Therapeutics - Technologies, Markets and Companies
The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways
Analysis of European Biosimilars Market
|
|
|
|
